A detailed history of Gsa Capital Partners LLP transactions in Verona Pharma PLC stock. As of the latest transaction made, Gsa Capital Partners LLP holds 29,513 shares of VRNA stock, worth $1.04 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
29,513
Holding current value
$1.04 Million
% of portfolio
0.06%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$15.46 - $30.16 $456,270 - $890,112
29,513 New
29,513 $849,000
Q2 2023

Aug 14, 2023

BUY
$19.41 - $23.43 $571,275 - $689,591
29,432 New
29,432 $622,000
Q2 2022

Aug 09, 2022

SELL
$3.55 - $5.06 $46,682 - $66,539
-13,150 Closed
0 $0
Q1 2022

May 11, 2022

BUY
$4.82 - $6.98 $63,383 - $91,787
13,150 New
13,150 $66,000

Others Institutions Holding VRNA

About Verona Pharma plc


  • Ticker VRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,954,200
  • Market Cap $2.16B
  • Description
  • Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...
More about VRNA
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.